Stroke remains a common vascular event with high mortality and morbidity. After heart disease, stroke is the second leading cause of death worldwide in adult persons. Silent or subclinical stroke is likely to occur with even greater frequency than clinical stroke and increases the risk of subsequent cerebrovascular events. Hypertension is by far the single most important controllable risk factor for stroke. The relationship between blood pressure (BP) and stroke mortality is strong, linear, and continuous in subjects with levels of BP higher than 115/75 mm Hg. Blood pressure reduction by antihypertensive treatment is clearly efficacious in the prevention of stroke (both primary and secondary). Although meta-analyses suggest that BP reduction, per se, is the most important determinant for stroke risk reduction, the question is if specific classes of antihypertensive drugs offer special protection against stroke is still controversial. Some studies have suggested that angiotensin receptors blockers (ARBs) appear to offer additional protection against stroke. This has been hypothesized in studies in hypertensives, such as LIFE and SCOPE, and especially in the only comparative trial focused on secondary stroke prevention. In the MOSES trial, the comparison of eprosartan versus nitrendipine in patients with a previous stroke resulted, despite a similar BP reduction, in a significant reduction in the primary composite endpoint of total mortality plus cardiovascular and cerebrovascular events, including recurrent events. These results may suggest a blood pressure-independent effect of ARBs, which can be mediated through several mechanisms, including their ability to counteract other markers of target organ damage, but also through a direct neuroprotective effect.
Introduction
Cardiovascular disease is the leading cause of death and disability worldwide [Lopez et al. 2006 ]. Stroke is the second commonest cause of mortality and remains the leading one of adult physical disability. The incidence of stroke is continuously growing as a consequence of an ageing population and is now emerging as a major problem in developing countries [Brainin et al. 2007 ].
Risk factors for stroke include those that are nonmodifiable (age, male sex, nonwhite ethnicity, family history, previous stroke) as well as those that are modifiable: hypertension, diabetes mellitus, atrial fibrillation, carotid artery disease, hyperlipidemia, cigarette smoking, obesity and high alcohol consumption [European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee, 2008; Goldstein et al. 2006 ].
Hypertension is by far the single most important controllable risk factor for stroke. The relationship between blood pressure (BP) and stroke mortality is strong, linear, and continuous in subjects with levels of BP higher than 115/75 mm Hg [Lewington et al. 2002] . Between ages of 40 and 70 years, each 20 mm Hg increase in systolic BP or 10 mm Hg increase in diastolic BP is associated with an approximate doubling of stroke mortality [Dahlof, 2008] . All components of BP are implicated in this increased cardiovascular risk, but in recent years systolic hypertension and elevated pulse pressure have been recognized as the main factors in the elderly.
Large differences in incidence, prevalence and mortality related to stroke have been observed among countries. This has been attributed to differences in risk factors, especially in hypertension prevalence [Wolf-Maier et al. 2003] . A recent study carried out in Spain have shown that even in the same country, differences in stroke mortality throughout different areas were associated with indexes of worse BP handling, low BP control rates and high left ventricular hypertrophy [Redón et al. 2007 ].
Stroke and myocardial infarction share some common risk factors and pathophysiological mechanisms. Compared with the general population, stroke patients have an increased risk of death from coronary heat disease [Amarenco and Steg, 2008] . A quarter of all stroke patients have a history of symptomatic coronary event [ArenTouzé et al. 2005] , and more than 50% of the patients with symptomatic intracranial atherosclerosis and no overt coronary artery disease show myocardial perfusion defects on stress-rest SPECT [Arenillas et al. 2005 ]. On the other hand, the REACH registry has shown that 40% of stroke patients have one or two other locations of vascular disease such as coronary disease and peripheral arterial disease [Bhatt et al. 2006 ]. Silent brain infarct and cerebral white matter lesions: pathogenesis and relation to arteriosclerosis and stroke Silent or subclinical stroke is likely to occur with even greater frequency than clinical stroke and increases the risk of subsequent cerebrovascular events. Silent brain infarcts are frequently seen on magnetic resonance imaging (MRI) in elderly people. The prevalence of these asymptomatic lesions (lacunaes or white matter lesions [WML]) increases with age from 5% at 60 years of age to 35% at 90 years of age. The terms 'lacuna', 'lacunar infarct' and 'lacunar stroke' are often used interchangeably, but there are not the same things. Lacunaes are 3-15 mm cerebrospinal fluid filled cavities in the basal ganglia or white matter, frequently observed coincidentally on imaging in older people, often not clearly associated with discrete neurological symptoms. The term lacunar infarct should be reserved for lesions that were clearly associated with a clinical lacunar syndrome [Wardlaw, 2008] . Lacunaes may cause typical lacunar syndromes but may also be clinically silent. The cardiovascular risk factors for silent brain infarcts are similar to those for stroke [Das et al. 2008; Vermeer et al. 2003 ].
The pathogenesis of WML is poorly understood, although the majority of studies have found that age, hypertension, diabetes mellitus and a history of stroke or heart disease are the most important factors related to WML. The main hypothesis regarding the association between high blood pressure and ischaemic WML is that long-standing hypertension causes lipohyalinosis of the media and thickening of the vessels walls with narrowing of the lumen of the small perforating arteries and arterioles which nourish the deep white matter. The perforating vessels, which originate in the cortical and leptomeningeal arteries, have a relatively poor anastomotic system, which makes the white matter vulnerable to cerebral ischaemia [De la Sierra and Sierra, 2006 ].
Postmortem studies have indicated that WML observed on magnetic resonance imaging scans are associated with atherosclerosis-related degenerative changes in arterioles, suggesting that these abnormalities in penetrating vessels are the main factor in the pathogenesis of ischaemic WML, and they are related to atherosclerosis, indicated by carotid intima-media thickness and carotid plaques [Sierra et al. 2002; Pantoni and García, 1995] . Diabetes mellitus and hypertension are associated with WML, but the relationship with lipid abnormalities and smoking status is controversial. Some studies have reported a relationship of WML with a history of stroke, lacunar infarcts, heart disease and atrial fibrillation, which are frequently associated with both hypertension and vascular risk factors.
High blood pressure has been reported to influence the presence and severity of WML in most studies. A group of investigators in Holland conducted a prospective study and found that both systolic and diastolic BP assessed 20 years earlier, were significantly associated with WML [De Leeuw et al. 1999] . Cerebral WML are important prognostic factors for the development of stroke, stroke recurrency, cognitive performance and dementia [De la Sierra and Sierra, 2006 ].
Prevention of stroke in patients with hypertension
Patients who have had a stroke or a transient ischemic attack (TIA) are at high risk for recurrent cerebrovascular and cardiac events. Lowering blood pressure reduces both stroke and coronary risks, depending on the magnitude of the reduction. Previous evidence supports the hypothesis that most strokes occur in treated patients, but with uncontrolled blood pressure. In a study carried out in Malmö, Sweeden [Li et al. 2005a ], a total de 17and 936 individuals aged 45-73 years were followed for a mean of 6 years. Of those treated, rates of stroke were 705 per 100and 000 patient-years in those with BP4140/90 mm Hg and 845 per 100and 000 patient-years in those with BP4160/100 mm Hg; in contrast, stroke incidence was only 289 per 100and 000 patient-years in subjects who achieved BP control (5140/90 mm Hg). In the same cohort studied normotensives exhibited stroke rates of 90 per 100and 000 patient-years [Li et al. 2005b ].
Blood pressure reduction by antihypertensive treatment is clearly efficacious in the prevention of stroke (both primary and secondary). Metaanalyses have demonstrated that BP reduction, per se, is the main determinant of stroke risk reduction. Lowering BP with antihypertensive treatment reduces stroke risk by 30-40%. The Blood Pressure Lowering Trialists' Collaboration, which reviewed 29 randomized controlled trials, found that the largest BP reduction promoted the most important protection against stroke [Turnbull et al. 2003 ].
In addition to the effect of BP lowering, the possibility of a BP-independent protective effect of specific classes of antihypertensive drugs is still controversial [De la Sierra and Sierra 2006] . In this regard, the analysis of controlled trials comparing beta-blockers with other antihypertensive treatment found that the relative risk of stroke was 16% higher with beta-blockers than with the other antihypertensive drugs [Lindholm et al. 2005 ]. On the other hand, numerous trials of ACE inhibitors have failed to demonstrate consistent benefits in stroke protection beyond blood pressure lowering [Staessen et al. 2003 ], although the results of the PROGRESS study showed that after stroke, lowering blood pressure with a combination of an ACE inhibitor and a diuretic reduced the rates of recurrent stroke [PROGRESS Collaborative Group, 2001 ]. Interestingly, this protective effect was absent in those patients treated with the ACE inhibitor alone, in contrast with those receiving the combination of perindopril and indapamide.
Angiotensin receptor blockers and cerebrovascular protection
Primary prevention of stroke in hypertensives The effect of ARBs on cardiac and cerebrovascular disease has been investigated in several clinical trials, both placebo-controlled and in comparative studies against other antihypertensive drugs. Whereas most studies conducted in cardiac patients with left ventricular dysfunction after myocardial infarction or with congestive hear failure have failed to show a superiority of ARB against usual treatment with ACE inhibitors, the effect or ARB on stroke prevention, both primary and secondary, has usually demonstrated to be superior to other antihypertensive drug classes, suggesting these drugs having a special effect on cerebrovascular protection.
The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study [Dahlöf et al. 2002] compared the ARB losartan and the betablocker atenolol in 9193 hypertensive patients older than 55 with electrocardiographically demonstrated left ventricular hypertrophy. The primary endpoint (a combination of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) was significantly reduced in losartan-treated patients. The relative risk of losartan compared to atenolol was 0.87 (95% CI: 0.77-0.98; p ¼ 0.021). Almost all differences were due to stroke prevention (fatal and nonfatal), being the relative risk for losartan compared to atenolol for stroke 0.75 (95% CI: 0.63-0.89; p ¼ 0.001), whereas reductions in myocardial infarction and cardiovascular death were nonsignificant.
The Study on Cognition and Prognosis in the Elderly (SCOPE) [Lithell et al. 2003 ] compared the ARB candesartan against placebo in 4964 elderly patients (70-89 years) with mild to moderate hypertension (systolic BP 160-179 and diastolic BP 90-99 mmHg). Open-label antihypertensive drugs were allowed as add-on treatment in order to achieve BP control. As a consequence, most patients (75% in the candesartan group and 84% in the placebo group) received antihypertensive agents apart from study drugs. There were significant differences in BP reduction between treatments that favoured candesartan (3.2/1.6 for systolic and diastolic BP, respectively, at the end of the study). This trial failed to demonstrate a significant difference in the primary endpoint (a composite of cardiovascular death, stroke and myocardial infarction). However, as in the LIFE trial, whereas no effect was observed on cardiac events, the candesartan treatment regimen reduced stroke (24%; p ¼ 0.056) and, in particular, nonfatal stroke (28%; p ¼ 0.04).
Secondary prevention of stroke: the MOSES study
The Morbidity and mortality after Stroke, Eprosartan compared with nitrendipine for Secondary prevention (MOSES) study is the first trial in secondary stroke prevention to compare antihypertensive agents [Schrader et al. 2005] . In this study, 1405 hypertensive stroke survivors were randomized to the ARB eprosartan or the calcium channel blocker nitrendipine during a mean of follow-up of 2.5 years. Nitrendipine was chosen as a comparative drug on the basis of the cardiovascular and cerebrovascular protection observed in trials conducted in patients with isolated systolic hypertension [Staessen et al. 2000 [Staessen et al. , 1997 and due to the fact that calcium channel blockers seem to be more protective against stroke than other antihypertensive drug classes in meta-analyses [Angeli et al. 2004; Turnbull et al. 2003 ]. Open antihypertensive treatments were allowed in order to achieve target BP and both BP control and mean BP values were essentially the same in both groups. The principal results of the MOSES trial revealed the superiority of eprosartan over nitrendipine in the primary endpoint (a composite of deaths and nonfatal cerebrovascular and cardiovascular events, including recurrent events). There were 206 primary endpoints in the eprosartan group (incidence density per 100 persons-years (ID) of 13.25) and 255 primary endpoints in the nitrendipine group (ID 16.71 ). The risk reduction for eprosartan was 21% with confidence limits from 4% to 34% (p ¼ 0.014). Separate analysis of the different components of primary endpoint also revealed a superiority of eprosartan over nitrendipine in the total number of cerebrovascular events, including recurrent events (relative risk reduction of 25% with confidence limits between 3% and 24%; p ¼ 0.026) and, although nonsignificant, in the total number of cardiovascular vents, including recurrent events (relative risk reduction of 25%, p ¼ 0.061).
In addition, MOSES investigators also analyzed the first occurrence of events in each category. There were no significant differences between eprosartan and nitrendipine in the first-time occurrence of cerebrovascular events and death from any cause, but, once more, eprosartan was superior to nitrendipine in the prevention of the first cardiovascular event (risk reduction of 31% with confidence limits between 3% and 50%; p ¼ 0.031). This better protection was essentially due the reduction in the incidence of myocardial infarction and new-onset heart failure.
After the results of these studies, the evidence supporting ARBs in stroke prevention was most consistent [Dahlö f 2008; De la Sierra and Sierra 2006] . Recently, the ONTARGET trial have compared the ARB telmisartan against the ACE inhibitor ramipril in patients at high-risk for cardiovascular events. Both treatment were equally effective in reducing cardiovascular endpoints, although protection against stroke was slightly better (nonsignificant) in telmisartan-treated patients [ONTARGET Investigators 2008] . In Japanese patients, also additional benefits are also achievable when an ARB is added to an already aggressive BP-lowering treatment regimen, as was shown in the Jikei Heart study [Mochizuki et al. 2007] , where relative stroke reduction reached 40%, even a small difference in BP was observed in favour of the group treated with valsartan.
Possible mechanisms of cerebrovascular protection with ARB Several different mechanisms have been proposed to explain the better cerebrovascular outcome in patients treated with an ARB, including left ventricular hypertrophy regression, protection against atrial enlargement and supraventricular arrhythmias, effects on endothelial function, risk biomarkers and vascular remodelling, and a specific neuroprotection mediated thorough angiotensin II and the angiotensin II type 2 (AT2) receptor [Sierra and de la Sierra, 2005] .
In the LIFE trial, the cardiovascular protection observed was related to left ventricular hypertrophy regression [Devereux et al. 2004; Okin et al. 2004] . Supraventricular arrhythmias are also frequent in hypertensive patients with diastolic dysfunction related to the increase in ventricular mass, which promotes atrial enlargement. It is recognized that atrial fibrillation is one of the main risk factors for stroke, especially when accompanied by hypertension, older age, or left ventricular dysfunction. A post-hoc analysis of the LIFE trial revealed that rates of new onset atrial fibrillation were significantly reduced in losartan-treated patients compared with those who received atenolol [Wachtell et al. 2005] , and some experimental data suggest that ARB can have a direct effect on atrial electrical remodelling [Nakashima et al. 2000 ].
In addition, there is growing experimental evidence suggesting that some actions directly related to the stimulation of the AT2 receptor may be involved in the cerebroprotection of ARB. Several angiotensin receptors mediate angiotensin II actions. Most of the deleterious effects of angiotensin II are mediated by the AT1 receptor, which is selectively blocked by ARB. Conversely, stimulation of the AT2 receptor by the same angiotensin II seems to promote vasodilation, natriuresis and apoptosis and impairs cellular hyperplasia [Fournier et al. 2004] . Some preliminary data support the idea that the AT2 receptor is expressed more intensively in the brain that in the heart and that this expression is enhanced in patients with target organ damage, especially when cerebral ischemia occurs. In experimental models, the AT2 receptor stimulation protects brain tissue from ischemia [Li et al. 2005c] . Treatment with an ARB would increase angiotensin II concentration locally, thus promoting the availability of this angiotensin II to bind the AT2 receptor and to mediate the mentioned beneficial actions. Other forms of RAS blockade, such as treatment with ACE inhibitors or direct renin inhibitors, would decrease angiotensin II and thus would not share the beneficial effects mediated through the AT2 receptor stimulation.
The PRoFESS trial
The recently reported PRoFESS trial randomly assigned 20 322 patients aged 55 years or older who had a recent (590 days) ischaemic stroke of arterial origin to receive telmisartan (80 mg daily) once per day (n ¼ 10 146) or placebo (10 186) on a background of standard blood-pressure-lowering treatment. After a mean of follow-up of 2.5 years, mean systolic BP was lower by 3.8 mm Hg and the mean of diastolic BP by 2 mm Hg among the patients assigned to telmisartan compared with those taking placebo: there was no significant difference in the rate of recurrent stroke (8.7% versus 9, 2% respectively; HR 0.95, 95% CI 0.86-1.04), or major vascular events (13.5% telmisartan versus 14,4% placebo; HR 0.94, 95% CI 0.87 to 10.1) ]. In addition, patients were randomly assigned to receive 75 mg clopidogrel once a day (n ¼ 10 151) or the combination of 25 mg aspirin and 200 mg extended-release dipyridamol twice per day (n ¼ 10 181). After a mean of 2.5 years, there were no differences in recurrent strokes (9.0% for aspirin with extended-release dipyridamol versus 8.8% for clopidogrel; hazard ratio (HR) 1.01, 95% CI 0.92 to 1.11) or the composite of stroke, myocardial infarction, or vascular death (13.1% aspirin with extended-release dipyridamol versus 13.1% clopidogrel; 0.99, 0.92 to 1.07) ]. In addition, disability due to recurrent stroke and cognitive decline in patients with ischaemic stroke were not different between the two antiplatelet regimens and were not affected by the preventive use of telmisartan.
The results of a post-hoc analysis suggested that the longer patients were exposed to telmisartan, the lower the risk of recurrent stroke ] (0-6 months: 3.4% telmisartan versus 3.2% placebo, OR: 1.07, 95% CI: 0.92-1.25; 46 months: 5.3% telmisartan versus 6.0% placebo, OR: 0.88, 95% CI: 0.78-0.99). The results for longer than 6 months are only hypothesis-generating, but they are biologically plausible. These results probable teach us that the aim to prevent complications related to hypertension require a prolonged follow-up for longer than a few years to fully appreciate the potential effect [Hankey and Eikelboom, 2008] .
Negative results observed in the PRoFESS trial are in contrast with MOSES observation of the superiority of eprosartan versus nitrendipine and also with the aforementioned hypothesis of a better cerebrovascular protection with ARB suggested in other studies and meta-analyses [Reboldi et al. 2008] . Reasons for these discrepancies may yield in some differences in the type of patient included. In this view, subjects in the PRoFESS trial were mostly included immediately after the event, whereas in other trials treatment was established generally later than 6 months after the stroke. It can be speculated that treating hypertension promotes protection once the event has been stabilized, whereas immediately after the stroke, treatment can increase the risk of mortality in patients susceptible to other comorbidities, such as infection, dehydration, and so on.
In addition, differences among ARB may have also affected the results. In this regard, we can speculate that better results obtained with eprosartan could be related to the dual mechanism of action of this agent. In fact, in addition to the renin-angiotensin system (RAS), the sympathetic nervous system (SNS) seems to play an important role in the pathogenesis of essential hypertension, metabolic syndrome and target organ damage related to elevated BP. Angiotensin II type 1 receptors located postjunctionally in the vascular bed promote vasoconstriction, whereas those located prejunctionally increase norepinephrine outflow to the junctional area, thus contributing to further vasoconstriction. The effect of several ARB (eprosartan, candesartan, valsartan and embusartan) on presynaptically and postsynaptically located AT1 receptors was investigated in the pithed rat model. Whereas the effect on postsynaptic receptors was dosedependent for all ARB, the sympathoinhibitory potency was clearly superior for eprosartan compared with other ARB [Balt et al. 2001 ]. Moreover, another study comparing eprosartan and losartan on both sympathoinhibitor and direct contractile responses in the canine pulmonary artery [Guimaraes et al. 2001 ] found a parallel effect of both eprosartan and losartan on direct contractile responses induced by angiotensin II, whereas at the prejunctional level, while eprosartan antagonized the facilitatory effect on noradrenaline release at the same doses that were effective postjunctionally, losartan was ineffective even at concentrations ten times higher than those used to block the receptor postjunctionally. This effect of eprosartan on SNS has also been confirmed in humans. In a comparative study against valsartan, eprosartan significantly reduced several hemodynamics parameters obtained after adrenergic and noradrenergic stress [Arosio et al. 2005 ].
In conclusion, antihypertensive treatment seems to be very efficacious in protecting patients against stroke and stroke recurrency, especially on a long-term basis. Even considering that the BP lowering effect is the most important factor in cerebrovascular protection [Mancia et al. 2007] , previous studies and a meta-analysis [Reboldi et al. 2008] suggest that, among antihypertensive drug classes, ARB could be more protective than other agents, although this hypothesis still needs further demonstration. Possible explanations for this suggestion include theoretical beneficial actions on other cardiovascular risk factors and organ damage (left ventricular and atrial remodelling), but also a direct neuroprotective effect mediated through the AT2 stimulation. At the present time, this has been translated into the clinical arena in the MOSES trial, where eprosartan showed a blood pressure-independent protective effect in comparison to the calcium channel blocker nitrendipine in the secondary prevention of stroke.
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